Results 41 to 50 of about 1,327 (120)

The role of radiotherapy in the treatment of oligometastatic non-small cell lung cancer

Reports of Practical Oncology and Radiotherapy
In the recent years, the clinical stage where the cancer has spread beyond the primary site, but has not yet metastasised extensively, and which is known as oligometastatic disease (OMD), has become an object of interest to radiation oncologists.
Radovan Vojtišek
doaj   +1 more source

Hypofractionated Image-Guided Radiation Therapy With Simultaneous-Integrated Boost Technique for Limited Metastases: A Multi-Institutional Analysis

Frontiers in Oncology, 2019
Purpose: To perform a multi-institutional analysis following treatment of limited osseous and/or nodal metastases in patients using a novel hypofractionated image-guided radiotherapy with simultaneous-integrated boost (HIGRT-SIB) technique.Methods ...
Corbin D. Jacobs, Manisha Palta, Manisha Palta, Hannah Williamson, Jeremy G. Price, Brian G. Czito, Brian G. Czito, Joseph K. Salama, Joseph K. Salama, Michael J. Moravan, Michael J. Moravan   +10 more
doaj   +1 more source

Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping–Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report [PDF]

Case Reports in Oncological Medicine
Javier David Benitez Fuentes, Miguel Borregón, Antonio David Lázaro Sánchez   +2 more
exaly   +2 more sources

Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression

Liver Cancer
Introduction The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized.
Tsung-Hao Liu, San-Chi Chen, Kun-Ming Rau, Li-Chun Lu, Po-Ting Lin, Yung-Yeh Su, Wei Teng, Shiue-Wei Lai, Ren-Hua Yeh, Tsui-Mai Kao, Pei-Chang Lee, Chi-Jung Wu, Chien-Hung Chen, Chih-Hung Hsu, Shi-Ming Lin, Yi-Hsiang Huang, Li-Tzong Chen, Ann-Lii Cheng, Ying-Chun Shen   +18 more
doaj   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 333-350, June 2026.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Expert Consensus on the Combined Application of Radiotherapy and Novel Systemic Agents in Breast Cancer Treatment

Journal of Evidence-Based Medicine, Volume 19, Issue 2, June 2026.
ABSTRACT The rapid advancement of radiotherapy techniques and systemic anticancer agents has created unprecedented opportunities to improve outcomes for breast cancer patients, while also introducing new challenges related to optimal integration and safety.
Jie Lan, Wenyi Zhou, Qiufan Zheng, Lu Cao, Wenyan Chen, Zhenyu He, Chunling Jiang, Yanchu Li, Wen Xia, Huihua Xiong, Xiaoli Yu, Jun Zhang, Jianli Zhao, Yanxia Zhao, Lei Liu, Xin Wu, Shusen Wang, Xiaobo Huang, Jing Jing   +18 more
wiley   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao, Zhi Fang, Kaitai Liu, Hua Ye, Jing Zhang, Yunbao Xu, Haoxun Mao, Chen Zhang, Chuangzhou Rao   +19 more
wiley   +1 more source

Advances and Prospects of Stereotactic Radiosurgery and Stereotactic Ablative Body Radiotherapy: Evolving Paradigms in Precision Oncology

Med Research, Volume 2, Issue 1, Page 157-180, March 2026.
The graphical abstract outlines the progressive development and impact of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). Technological Evolution illustrates the transition from brachytherapy with single‐dose, LDR/HDR schedules to fractionated radiotherapy, three‐dimensional conformal radiotherapy (3DCRT) and Gamma Knife ...
Jing Zhang, Wenhao Xu, Weiqing Lu, Yingxuan Lin, Luoxi He, Zonglin Lv, Yiliyaer Nuerrula, Zouting, Zhen Zhang, Hailiang Zhang, Xuejun Ma   +10 more
wiley   +1 more source

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

BMC Cancer, 2021
Background Despite the wide-spread use of immune checkpoint inhibitors (ICIs) in cancer chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are scarce.
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, Toru Kumagai, Akihiro Tamiya, Yoshihiko Taniguchi, Toshihide Yokoyama, Tadashi Ishida, Hirotaka Matsumoto, Katsuya Hirano, Ryota Kominami, Keisuke Tomii, Hidekazu Suzuki, Tomonori Hirashima, Satoshi Tanaka, Junji Uchida, Mitsunori Morita, Masaki Kanazu, Masahide Mori, Kenji Nagata, Ikue Fukuda, Motohiro Tamiya   +21 more
doaj   +1 more source

Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non‐Small Cell Lung Cancer With ROS1 Rearrangement

Cancer Medicine, Volume 15, Issue 2, February 2026.
Survival outcomes in gradual/local progression group were superior to dramatic progression group; survival period of dramatic progression group who received chemotherapy was longer than that of other therapies. ROS1 kinase domain mutations were detected predominantly in dramatic progression group, whereas activation of bypass and downstream pathways ...
Quan‐Quan Tan, Yu‐Qing Chen, Yu‐Er Gao, Ke‐Jun Liu, Zi‐Ji Mao, Ming‐Ying Zheng, Jun‐Wei Su, Jiao Yang, Qing‐Yun Gao, Hua‐Jun Chen, Jin‐Ji Yang   +10 more
wiley   +1 more source